- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MannKind Corp (MNKD)
Track today's live MannKind (MNKD) share price, performance and key data on this page with our current NASDAQ:MNKD stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the MannKind share price on the NASDAQ exchange. Use the dropdown to switch exchange for the MNKD share price, head to our technical summary section, which provides analysis on MannKind share price buy/sell indicators using real-time data (or discuss the MannKind (MNKD) stock price today with other investors in the MannKind NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:MNKD share price (ISIN: US56400P7069) to enhance your trading decisions with our free investment tools and resources.
What Is the MannKind Corp Share Price Today?
The MannKind share price today is 4.150.
What Is the Stock Symbol for MannKind Corp
The stock symbol (or 'ticker') for MannKind Corp is "MNKD."
What Stock Exchange Does MannKind Corp Trade On?
MannKind Corp is listed and trades on the NASDAQ stock exchange.
Is MannKind Corp a Good Stock to Buy?
Determining whether MannKind (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:MNKD share price (ISIN: US56400P7069) to enhance your trading decisions with our free investment tools and resources.
What Is the MannKind Corp Share Price Today?
The MannKind share price today is 4.150.
What Is the Stock Symbol for MannKind Corp
The stock symbol (or 'ticker') for MannKind Corp is "MNKD."
What Stock Exchange Does MannKind Corp Trade On?
MannKind Corp is listed and trades on the NASDAQ stock exchange.
Is MannKind Corp a Good Stock to Buy?
Determining whether MannKind (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.110
4.355
52 wk Range
2.230
6.510
MNKD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.1104.355
52 wk Range
2.2306.510
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MNKD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
7.969
Upside
+92.02%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Not profitable over the last twelve months
MannKind earnings matched, revenue topped estimates- Investing.com
MannKind Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.969
(+92.02% Upside)
MannKind Corp Earnings Call Summary for Q2/2026
- MannKind Q2 revenue hit $109.4M, up 43% YoY and beating estimates; EPS of -$0.01 matched forecasts despite GAAP net loss widening to $19M.
- Marketed products revenue surged 111% YoY; Afrezza pediatric launch and FUROSCIX ReadyFlow approval drove growth with $17M and $22.2M sales respectively.
- Company maintained FUROSCIX full-year guidance of $110M-$120M; expects H2 strength from seasonal patterns and improved patient affordability.
- R&D and SG&A expenses jumped 31% and 84% respectively as firm invests in launches; $45M CVR payment and $16M related charge due in Q3.
- Stock rose 4.55% to $4.14 in regular trading but fell 3.45% after-hours as investors weighed strong revenue momentum against rising costs.
Last Updated: 05/08/2026, 22:44
Read Full TranscriptEarnings
Latest Release
05/08/2026
EPS / Forecast
-0.01 / -0.01
Revenue / Forecast
109.37M / 109.02M
Compare MNKD to Peers and Sector
Metrics to compare | MNKD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNKDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −30.6x | 4.9x | −0.4x | |
PEG Ratio | 0.12 | −0.04 | 0.00 | |
Price/Book | −19.9x | 3.0x | 2.6x | |
Price / LTM Sales | 3.4x | 4.3x | 3.1x | |
Upside (Analyst Target) | 80.7% | 479.5% | 48.9% | |
Fair Value Upside | Unlock | 16.9% | 6.2% | Unlock |
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company’s pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the MannKind (NASDAQ: MNKD) Share Price Today?
The MannKind stock price today is 4.150 USD.
What Stock Exchange Does MannKind (MNKD) Trade On?
MannKind is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for MannKind?
The stock symbol (also called a 'ticker') for MannKind is "MNKD."
What Is the Current MannKind Market Capitalisation?
As of today, MannKind (NASDAQ: MNKD) market cap is 1.330B USD.
What Is MannKind's (MNKD) Earnings Per Share (TTM)?
The MannKind EPS is currently -0.158 (Trailing Twelve Months).
When Is the Next MannKind Earnings Date?
MannKind's next earnings report will be released on 10/11/2026.
Is MNKD a Buy or Sell From a Technical Analyst Perspective?
Based on today's MannKind moving averages and other technical indicators, the daily buy/sell signal for MNKD stock is Strong Buy.
How Many Times Has MannKind Stock Split?
MannKind has split 1 times. (See the MNKD stock split history page for full effective split date and price information.)
How Many Employees Does MannKind Have?
MannKind has 592 employees, based on their latest Companies House report.
What is the current trading status of MannKind (NASDAQ: MNKD)?
As of 23/08/2026, MannKind (MNKD) is trading at a share price of 4.150 USD, with a previous close of 4.260 USD. The stock has fluctuated within a day range of 4.110 USD to 4.355 USD, while its 52-week range spans from 2.230 USD to 6.510 USD.
What Is MannKind (MNKD) Price Target According to Analysts?
The average 12-month price target for MannKind is 7.969 USD, with a high estimate of 13 USD and a low estimate of 4.75 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +92.02% Upside potential.
What Is the MNKD Premarket Price?
MNKD's last pre-market stock price is 4.310 USD. The pre-market share volume is 1,610.000, and the stock has decreased by 0.050, or 1.170%.
What Is the MNKD After Hours Price?
MNKD's last after hours stock price is 4.120 USD, the stock has decreased by -0.030, or -0.720%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.